Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carlos Almonacid has a total of 221 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Eosinophilic inflammation in severe asthma: Pathophysiology, clinical identification, and therapeutic implications

    by Miguel Jiménez-Gómez, Carlos Almonacid-Sánchez, Marina Blanco-Aparicio, Hemily Izaguirre-Flores, Mariana Muñoz-Esquerre, Gerardo Pérez-Chica, Juan Luis García-Rivero, Alicia Padilla-Galo, José Gregorio Soto-Campos

    A critical step in the management of uncontrolled severe asthma—estimated to affect 3–4% of asthma patients (1)—is the identification of the inflammatory phenotype. Severe asthma is a heterogeneous...

  • Open Access

    Temporal trends in baseline severity and 12-month response to mepolizumab in severe asthma: The TYREX multicentre real-world study in Spain (2017–2024)

    by Javier Domínguez-Ortega, Carlos Almonacid, Francisco Javier Alvarez-Gutiérrez, Carolina Cisneros, Ignacio Dávila, David Bañas-Conejero, Esteban Antelo-Cea, Luis Pérez de Llano, Hemily Katerine Izaguirre Flores, Mariana Muñoz-Esquerre, et al.

  • Open Access

    Expert Opinion and Evidence-Based Review on Maintenance Therapy Step-Down in Patients With Severe Asthma Controlled With Biologics

    by Vicente Plaza, Gregorio Soto Campos, Juan Carlos Miralles López, Alicia Padilla Galo, Eva Martínez Moragón, Fernando Rodríguez, Mar Mosteiro, Pilar Ausín, Pilar Cebollero, Santiago Quirce, et al.

  • Inside GEMA 5.5: Expert Insights on the Latest Changes in Asthma Management

    by Carlos Almonacid, Santiago Quirce, Marina Blanco, Alfonso del Cuvillo, José Valverde-Molina, Vicente Plaza


  • Open Access

    Real-Life Experience with Cytomegalovirus Hyperimmune Globulin in a Lung Transplant Unit: Long-Term Outcomes

    by Raquel Sanabrias Fernández de Sevilla, Sarela García-Masedo Fernández, Rosalía Laporta Hernández, Myriam Aguilar Pérez, Christian García Fadul, María Teresa Lázaro Carrasco de la Fuente, Enrique Rodríguez Rubio, Amelia Sánchez Guerrero, Carlos Almonacid Sánchez, María Piedad Ussetti Gil

    Background/Objectives: Cytomegalovirus (CMV) infection is a frequent complication after lung transplantation, especially in high-risk donor-positive/recipient-negative (D+/R−) patients. CMV-specific hyperimmunoglobulin (CMV-HIG), administered either with antivirals or as monotherapy, may be beneficial for preventing or treating CMV infection in selected clinical scenarios. This study evaluated CMV-HIG indications and their impact on clinical outcomes in our lung transplant unit. Methods: We retrospectively analyzed adult lung transplant recipients (2010–2023) who received ≥2 doses of CMV-HIG for universal prophylaxis, monotherapy prophylaxis, preemptive therapy, or treatment of invasive disease. Results: CMV-HIG was administered to 204 out of 336 recipients (61%). CMV-HIG was well tolerated, with no treatment-related adverse events. Indications were preemptive therapy (63%), universal prophylaxis (24%), monotherapy prophylaxis (7%), and treatment of invasive disease (6%). CMV-HIG was well tolerated, with no treatment-related adverse events. No patients developed invasive disease during combination prophylaxis or preemptive treatment. The combination treatment of patients with invasive disease was also effective, and no cases of VGC resistance were detected. CMV-HIG monoprophylaxis has allowed us to delay or prevent viral replication in recipients who developed VGC side effects. Rates of acute rejection, Chronic Lung Allograft Dysfunction (CLAD), and overall survival were similar across CMV risk groups. Conclusions: Our results showed that the combined use of CMV-HIG and antiviral agents is effective in preventing CMV infection and disease in high-risk lung transplant recipients. This combination is also useful in treating invasive disease and preventing VGC resistance. Additionally, CMV-HIG monoprohylaxis can delay or prevent viral replication in recipients experiencing VGC-related side effects. These findings support the use of CMV-HIG in selected clinical settings, although prospective studies are needed to define its potential benefits within the current therapeutic armamentarium.

  • Open Access

    Optimising clinical trial management in Spain: The CARABELA-Clinical trials framework integrating healthcare models and subject experiences

    by Carlos Almonacid, Borja G. Cosío, Xavier Muñoz Gall, Jaime Signes-Costa, José Luis Velasco Garrido, Mercedes Luz, Marta Rodríguez, Alberto Godos, Ana Pérez Domínguez, Eunice Funenga, et al.


  • Open Access

    Equity in Respiratory Health: Actionable Recommendations for Spain

    by Carlos Almonacid, Joan B. Soriano, M. Guadalupe Fontán, Beatriz González López-Valcárcel, Carmen Hernández, Rafael Manzanera, Remedios Martel, Mariano Pastor, Virginia Rodríguez, Isabel Urrutia, et al.


  • Open Access

    Support Needs of Patients with Chronic Obstructive Pulmonary Disease (COPD) and Asthma Throughout Their Patient Journey: A Qualitative Study

    by Carlos Almonacid, Raquel Gómez, Ignacio Morán, Irantzu Muerza, Mariano Pastor, Paula Garcia-Esparcia, Elena García, Cristina Soria, Esther Lázaro, Dolors Querol

    Purpose: Chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, pose a significant health risk due to the increasingly pronounced rise in its prevalence, associated complications and impact on patients’ quality of life. The aim of this study is to analyse the needs of patients with COPD and asthma throughout their patient journey. Patients and Methods: To this end, a qualitative and cross-sectional study was conducted based on interviews and focus groups. 28 people took part, including patients, relatives and representatives of patient associations, and they were selected to ensure a diversity of perspectives. The data collected were analyzed by two psychologists with experience in qualitative research, who conducted thematic analysis and made use of data saturation criteria. Results: The results emphasize that patient needs vary according to the stage of the disease. In the initial stage, patients find it difficult to identify symptoms and risk factors, and demand education on basic concepts and self-care strategies. When diagnosed, they require psycho-emotional support and training on the disease. Insufficient information, particularly concerning the use of inhalers and the different therapies, is a recurrent obstacle in treatment and monitoring. Furthermore, therapeutic nonadherence is affected by factors such as perception of the severity of the disease, related to the treatment and deficiencies in inhaler technique. Additionally, pulmonary rehabilitation and multidisciplinary care are unmet needs that have an impact on patients’ quality of life. Conclusion: The study highlights the importance of personalizing interventions according to the stage of the patient journey, combining education, disease coping strategies and comprehensive monitoring. Patient groups play a key role as they are a source of emotional support, guidance and self-care. In conclusion, a proposal is made for a patient-centred approach that promotes self-management, equitable access to resources and coordination between healthcare teams to optimise integrated care in respiratory diseases. In this respect, it seems relevant and appropriate to develop training environments for patients diagnosed with asthma/COPD and their carers, where information and training are offered to support good disease management in the different stages of the patient journey.


  • Open Access

    Gestión de riesgos en la realización de pruebas de función pulmonar pospandemia

    by Luis Puente Maestu, Juana M. Martínez Llorens, José Luis Valera Felices, Yolanda Torralba García, Marian Gimeno Peribáñez, Eusebi Chiner, Roberto Cabestre, Juan Rodríguez Hermosa, Raúl Godoy Mayoral, Celeste Marcos, et al.


  • Open Access

    BALF Lymphocyte and Cytokine Profiling as Biomarkers of Acute Rejection After Lung Transplantation

    by Silvia Aguado Ibáñez, Carlos Almonacid Sanchez, Piedad Ussetti Gil

    Background: Acute cellular rejection (ACR) remains a common complication following lung transplantation and is a major risk factor for chronic lung allograft dysfunction (CLAD). Although transbronchial biopsy (TBB) is the diagnostic gold standard, it is invasive and may be contraindicated in certain patients. This study aimed to assess the diagnostic utility of combining bronchoalveolar lavage fluid (BALF) lymphocyte counts with cytokine profiling—particularly interleukin-17A (IL-17A)—in lung transplant recipients with elevated peripheral blood eosinophil (EOS) counts. Methods: We retrospectively analyzed 108 BALF and matched TBB samples from 74 lung transplant recipients with EOS counts >200 cells/μL, collected between 2014 and 2020. BALF lymphocyte percentages and levels of cytokines (IL-4, IL-6, IL-10, IL-13, IL-15, IL-17A, IFN-γ, TNF) were quantified. Associations with histologically confirmed ACR were evaluated using generalized estimating equation models. Results: ACR was diagnosed in 57% of TBB samples. BALF lymphocyte percentages were significantly higher in ACR cases (median 8% vs. 4%, p < 0.001). Each 1% increase in lymphocytes was associated with a 10% increase in the odds of ACR (OR 1.102; 95% CI 1.076–1.129). IL-17A levels were also significantly elevated in ACR (OR 1.047; 95% CI 1.003–1.092; p = 0.032), but with moderate discriminative ability (AUC = 0.629). The combination of BALF lymphocyte counts and IL-17A levels improved diagnostic performance (AUC > 0.76). Conclusions: The combined assessment of BALF lymphocyte counts and IL-17A levels in recipients with elevated EOS offers a promising non-invasive strategy to support the diagnosis of ACR. Prospective studies are needed to validate these findings and further refine personalized diagnostic approaches to ACR.